Veda N Giri, MD

Medical Oncology
Director, Prostate Cancer Risk Assessment
Assistant Professor in Cancer Prevention and Control, Medical Oncology, and Clinical Genetics

Meet other members of the
prostate cancer treatment team.
Meet other members of the
breast cancer treatment team.

Learn more about
Risk Assessment

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111-2497

New patients can request an appointment online or call 215-728-2570.

Appointments for Returning Patients

For general information, call:
1-888-FOX CHASE (1-888-369-2427).
An oncology certified nurse will assist you.

Clinical Expertise:

Breast Cancer; Prostate Cancer; Cancer Genetics

Medical Education:

Jefferson Medical College, Philadelphia, Pa., 1997

Residency:

Internal Medicine, University of Michigan Medical Center, Ann Arbor, Mich.

Fellowship:

Hematology-Oncology, University of Michigan Medical Center, Ann Arbor, Mich.

Certifications:

American Board of Internal Medicine;
Medical Oncology

Professional Societies:

American Society of Clinical Oncology;
American Association for Cancer Research;
American Society of Preventive Oncology

Scientific Report:

Medical Oncology: Clinical Trials Research;
DNA Repair of Mismatched Bases and Early Molecular Changes in Tumorigenesis;
The Prostate Cancer Risk Assessment Program
(These links require Adobe® Acrobat Reader to view.)

Research Interests:

Prostate Cancer;
Cancer Risk Assessment and Prevention

I believe that patients receive the best care by having a comprehensive evaluation in a receptive and understanding environment. With my background in medical oncology and translational cancer research, I am able to provide a unique experience to my patients with regard to the evaluation and treatment of cancer.

I joined the staff of Fox Chase in 2004. Since that time, I have been named the director of Prostate Cancer Risk Assessment. I was appointed to the National Institutes of Health Prostate Cancer Genetics PDQ Editorial Board. At Fox Chase, I am an active member of the IRB (Institutional Review Board) as well as the Executive Steering Committee.

The American Cancer Society awarded me the Special Interest Award to investigate the role of DNA mismatch repair defects in prostate cancer susceptibility. I also received a five-year career development grant from the Department of Defense to study genetic variants in prostate cancer risk. In the laboratory, I perform ongoing research into the genetic, molecular and proteomic pathways involved in cancer susceptibility, especially prostate cancer.